tech transfer – Page 75

Bioavailability risk flagged during regulatory review – regulatory expectations for formulation data

Managing Bioavailability Risks Identified During Regulatory Review: A Comprehensive Playbook In the pharmaceutical manufacturing landscape, the identification of bioavailability risks during regulatory review can pose significant challenges for formulation development…

Prototype not scalable during scale-up preparation – regulatory expectations for formulation data

Tackling Scalability Issues in Formulation Development: An Actionable Playbook In the realm of pharmaceutical manufacturing, the transition from prototype to scalable production can often present unforeseen challenges. A failure to…

Formulation fails stability targets during scale-up preparation – CMC risk assessment and mitigation

Mitigating Risks When Formulation Fails Stability Targets During Scale-Up Preparation In pharmaceutical development, the transition from small-scale formulation to large-scale production is fraught with risk. One of the most critical…

Dissolution variability unexplained during IND/NDA filing – CMC risk assessment and mitigation

Addressing Unexplained Dissolution Variability During IND/NDA Filing: A Comprehensive Playbook Dissolution variability during the Investigational New Drug (IND) and New Drug Application (NDA) filing can lead to significant delays, regulatory…

QbD elements missing during regulatory review – how to redesign formulation strategy

Identifying Missing QbD Elements During Regulatory Review and Redesigning Formulation Strategy In the pharmaceutical sector, the absence of Quality by Design (QbD) elements during regulatory reviews can lead to significant…

Excipient incompatibility identified late during scale-up preparation – how to redesign formulation strategy

Strategies for Addressing Late-Stage Excipient Incompatibility in Formulation Development During the critical phase of scale-up preparation, pharmaceutical development teams may encounter excipient incompatibility issues, which can severely impact timelines and…

Tech Transfer Failures? Documentation and Execution Solutions

Addressing Challenges in Tech Transfer Documentation and Execution In pharmaceutical manufacturing, tech transfer remains a critical process that underpins the successful scale-up of products from development to production. However, failures…

Process Not Scaling? Development and Control Strategy Solutions

Troubleshooting Process Development and Control Strategies for Successful Scaling In the complex landscape of pharmaceutical manufacturing, a common impediment faced during the scale-up phase is the failure to ensure that…

R&D Scale-Up Failures? Development-to-Manufacturing Solutions

Managing R&D Scale-Up Challenges: Solutions for Smooth Development to Manufacturing Transition The transition from research and development (R&D) to manufacturing can often encounter significant obstacles that impede the scale-up process.…

Site-to-Site Transfer Problems? Managing Multi-Site Manufacturing Risks

Managing Risks in Multi-Site Pharmaceutical Manufacturing Transfers The pharmaceutical industry faces significant challenges when conducting site-to-site transfers, especially when scaling up production. Frequent signals of failure can lead to costly…

Tech Transfer to CMOs/CDMOs Failing? Oversight and Control Strategies

When CMO and CDMO Tech Transfers Fail: Effective Oversight and Control Strategies Successful technology transfer to Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) is crucial for…

Incomplete Tech Transfer Documentation? What Regulators Expect

Inadequate Tech Transfer Documentation? Understand Regulatory Expectations In the highly regulated pharmaceutical manufacturing landscape, inadequate tech transfer documentation can lead to substantial compliance risks. This situation can trigger investigations, regulatory…